Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Pediatric Endocrinology · Classic Congenital Adrenal Hyperplasia

Balancing the Scale: Treatment Strategies for CAH

At a Glance

Classic CAH treatment requires a delicate balance of hydrocortisone to replace cortisol, fludrocortisone to replace aldosterone, and sometimes salt supplements. Regular monitoring ensures healthy child development while preventing the risks of over- or under-treatment.

Managing classic CAH is a delicate balancing act. The goal of treatment is to replace the hormones your child’s body cannot make while keeping other hormones from rising too high [1][2]. With the right plan, children with CAH can grow and develop just like their peers [3].

The Three Pillars of Treatment

Standard care for classic CAH typically involves three main components to restore the body’s natural chemistry.

1. Glucocorticoid Replacement (Cortisol)

In children, hydrocortisone is the preferred medication [4]. Because the body naturally releases cortisol in waves, doctors usually recommend giving hydrocortisone in three smaller doses throughout the day to mimic this rhythm [5].

  • The Balance: If the dose is too low (undertreatment), the brain will continue to “shout” at the adrenal glands, leading to high androgens, rapid but early growth, and the risk of a life-threatening adrenal crisis [6][7].
  • The Risk: If the dose is too high (overtreatment), it can slow down a child’s growth, cause excessive weight gain, and lead to other metabolic issues like high blood pressure [6][8].
  • Note on Stress Dosing: When your child is ill and needs “stress dosing,” it is only the hydrocortisone that gets increased. The fludrocortisone dose stays the same unless your doctor directs otherwise [9][10].

2. Mineralocorticoid Replacement (Aldosterone)

For children with the salt-wasting subtype, the medication fludrocortisone is used to replace aldosterone [11][12]. This helps the kidneys retain salt and maintain healthy blood pressure. Doctors monitor a blood marker called Plasma Renin Activity (PRA) to ensure the dose is correct [13][14].

3. Salt Supplementation

Infants with salt-wasting CAH often need extra sodium chloride (table salt) added to their formula or breast milk [15]. This is especially important in the first few months of life, as infants’ kidneys are not yet efficient at holding onto salt. Providing extra salt may actually help lower the amount of medication (fludrocortisone and hydrocortisone) the baby needs [15].

New Horizons: Crinecerfont

For years, the only way to lower high androgen levels was to give higher-than-normal (supraphysiological) doses of steroids. A new, FDA-approved medication called Crinecerfont offers a different approach [16][17].

  • How it Works: Crinecerfont is a “CRF1 receptor antagonist.” Instead of using high doses of steroids to “quiet” the brain’s signal to the adrenal glands, Crinecerfont blocks that signal directly [16][17].
  • The Benefit: By blocking the signal, it can lower adrenal androgens, allowing doctors to reduce the daily steroid dose toward a more natural, “physiological” level [16][18].
  • Eligibility: It is currently approved for patients aged 4 years and older [17]. While infants cannot use it immediately, it represents a highly promising option to help manage their long-term health as they grow.

Monitoring Success

Your pediatric endocrinologist will use several tools to make sure the treatment is on track:

  • Growth Charts: Regular measurements of height and weight are one of the most sensitive indicators of whether the steroid dose is balanced [1][2].
  • Hormone Checks: Blood tests for 17-hydroxyprogesterone (17-OHP) and androstenedione help determine if the medications are effectively controlling androgen levels [19][20].
  • Bone Age: Periodic X-rays of the hand and wrist can show if high androgens are causing the bones to mature too quickly [1].

For crucial information on how to handle illnesses and emergencies with this treatment, please read Adrenal Crisis: Preventing and Managing Emergencies.

Common questions in this guide

What are the main medications used to treat classic CAH?
Children with classic CAH typically take hydrocortisone to replace missing cortisol and fludrocortisone to help the body retain salt. Infants may also need extra sodium chloride (table salt) added to their milk or formula.
Why is getting the right steroid dose so important for my child?
Finding the exact right dose is a delicate balance. Too little steroid can lead to a dangerous adrenal crisis and early growth spurts, while too much can slow a child's overall growth and cause excessive weight gain.
Do I need to increase both CAH medications when my child gets sick?
No, when your child is ill and requires a stress dose, only the hydrocortisone gets increased. The fludrocortisone dose should stay the same unless your doctor gives you different instructions.
What is Crinecerfont and who can take it?
Crinecerfont is a new, FDA-approved medication that blocks the brain's signal to the adrenal glands, helping to lower androgen levels. This allows doctors to reduce daily steroid doses. It is currently approved for patients 4 years of age and older.
How do doctors monitor if the CAH treatment is working?
Pediatric endocrinologists use a combination of growth charts, hormone blood tests like 17-OHP, and bone age X-rays to ensure the medication is effectively controlling androgen levels without causing side effects.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my child currently on a 'physiological' dose of hydrocortisone, or is the dose higher (supraphysiological)?
  2. 2.How are my child's growth velocity and weight gain trending compared to the last visit?
  3. 3.Based on the most recent 17-OHP and androstenedione levels, is the current medication dose effectively controlling adrenal androgens?
  4. 4.If my child is over 4 years old, is Crinecerfont a potential option to help us lower their daily steroid dose?
  5. 5.At what age do you typically recommend we stop the daily salt (sodium chloride) supplements?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and Adolescence

    Peltek Kendirci HN, Ünal E, Dündar İ, et al.

    Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):12-22 doi:10.4274/jcrpe.galenos.2024.2024-6-26-S.

    PMID: 39713876
  2. 2

    Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Nokoff NJ, Buchanan C, Barker JM

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S13-S24 doi:10.1210/clinem/dgae563.

    PMID: 39836622
  3. 3

    [Long-term morbidity in congenital adrenal hyperplasia].

    Tschaidse L, Quitter F, Hübner A, Reisch N

    Der Internist 2022; (63(1)):43-50 doi:10.1007/s00108-021-01223-6.

    PMID: 34978615
  4. 4

    Congenital adrenal hyperplasia.

    El-Maouche D, Arlt W, Merke DP

    Lancet (London, England) 2017; (390(10108)):2194-2210 doi:10.1016/S0140-6736(17)31431-9.

    PMID: 28576284
  5. 5

    Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia.

    Prete A, Auchus RJ, Ross RJ

    European journal of endocrinology 2021; (186(1)):R1-R14.

    PMID: 34735372
  6. 6

    Cardiometabolic Aspects of Congenital Adrenal Hyperplasia.

    Krysiak R, Claahsen-van der Grinten HL, Reisch N, et al.

    Endocrine reviews 2025; (46(1)):80-148 doi:10.1210/endrev/bnae026.

    PMID: 39240753
  7. 7

    Arterial stiffness and shortened QTc interval are associated with androgen and ACTH levels in classic congenital adrenal hyperplasia.

    Campioni L, Di Carlo MC, Sola C, et al.

    Frontiers in endocrinology 2025; (16()):1660114 doi:10.3389/fendo.2025.1660114.

    PMID: 40917363
  8. 8

    Epidemiology and Long-Term Adverse Outcomes in Korean Patients with Congenital Adrenal Hyperplasia: A Nationwide Study.

    Kim JH, Choi S, Lee YA, et al.

    Endocrinology and metabolism (Seoul, Korea) 2022; (37(1)):138-147 doi:10.3803/EnM.2021.1328.

    PMID: 35255606
  9. 9

    Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: Guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK.

    Woodcock T, Barker P, Daniel S, et al.

    Anaesthesia 2020; (75(5)):654-663 doi:10.1111/anae.14963.

    PMID: 32017012
  10. 10

    Perioperative glucocorticoid management based on current evidence.

    Seo KH

    Anesthesia and pain medicine 2021; (16(1)):8-15 doi:10.17085/apm.20089.

    PMID: 33445232
  11. 11

    Comprehensive Analysis of Congenital Adrenal Hyperplasia Using Long-Read Sequencing.

    Liu Y, Chen M, Liu J, et al.

    Clinical chemistry 2022; (68(7)):927-939 doi:10.1093/clinchem/hvac046.

    PMID: 35714169
  12. 12

    Congenital Adrenal Hyperplasia.

    Fraga NR, Minaeian N, Kim MS

    Pediatrics in review 2024; (45(2)):74-84 doi:10.1542/pir.2022-005617.

    PMID: 38296783
  13. 13

    Congenital Adrenal Hyperplasia in Children: The Relationship between Plasma Renin Activity and Hypertension.

    Lubis SM, Soesanti F, Hidayati EL, Aap BT

    Iranian journal of medical sciences 2024; (49(6)):377-383 doi:10.30476/ijms.2023.98508.3058.

    PMID: 38952640
  14. 14

    Blood Pressure in a Large Cohort of Children and Adolescents With Classic Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency.

    Bonfig W, Roehl FW, Riedl S, et al.

    American journal of hypertension 2016; (29(2)):266-72 doi:10.1093/ajh/hpv087.

    PMID: 26071487
  15. 15

    Treatment of congenital adrenal hyperplasia in children aged 0-3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure.

    Neumann U, van der Linde A, Krone RE, et al.

    European journal of endocrinology 2022; (186(5)):587-596 doi:10.1530/EJE-21-1085.

    PMID: 35290211
  16. 16

    Crinecerfont: CRF1R Antagonist Approved for Treatment of Congenital Adrenal Hyperplasia.

    Yuan L

    The Annals of pharmacotherapy 2026; (60(5)):512-520 doi:10.1177/10600280251396594.

    PMID: 41321281
  17. 17

    Crinecerfont: First Approval.

    Lee A

    Drugs 2025; (85(6)):839-843 doi:10.1007/s40265-025-02165-1.

    PMID: 40240539
  18. 18

    Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.

    Auchus RJ, Hamidi O, Pivonello R, et al.

    The New England journal of medicine 2024; (391(6)):504-514 doi:10.1056/NEJMoa2404656.

    PMID: 38828955
  19. 19

    Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry.

    Lawrence N, Bacila I, Dawson J, et al.

    Clinical endocrinology 2022; (97(5)):551-561 doi:10.1111/cen.14796.

    PMID: 35781728
  20. 20

    The spectrum of CYP21A2 gene mutations in patients with classic salt wasting form of 2l-hydroxylase deficiency in a Chinese cohort.

    Liu Y, Zheng J, Liu N, et al.

    Molecular genetics & genomic medicine 2020; (8(11)):e1501 doi:10.1002/mgg3.1501.

    PMID: 32959514

This page provides educational information about CAH treatments. Always consult your pediatric endocrinologist before adjusting your child's steroid or medication doses.

Get notified when new evidence is published on Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.